Research and Reports on Genetics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Rapid Communication - Research and Reports on Genetics (2022) Volume 4, Issue 2

Gene clonality, tissue distribution analysis using next-generation sequencing of type I collagen alpha 1 gene

Ronghui Cowley*

Department of Laboratory Medicine

*Corresponding Author:
Ronghui Cowley
Department of Laboratory Medicine
Yonsei University College of Medicine
Seoul, Republic of Korea

Received:24-Feb-2022, Manuscript No.AARRGS -22-106; Editor assigned: 26-Feb-2022, PreQC No. AARRGS -22-106 (PQ); Reviewed:12-Mar-2022, QC No.AARRGS -22-106; Revised:17-Mar-2022, Manuscript No. AARRGS -22-106 (R); Published: 24-Mar-2022, DOI:10.35841/ aarrgs-4.2.106

Citation: Cowley R. Gene clonality, tissue distribution analysis using next-generation sequencing of type I collagen alpha 1 gene. J Res Rep Genet. 2022;4(2):106

Visit for more related articles at Research and Reports on Genetics


The request for collagen has been expanding over a long time due to its wide application in nourishment, beauty care products and biomedicine businesses. The blend of collagen protein in angle depends on informational given by collagen, sort I, alpha 1 (COL1A1) quality. In any case, cloning, tissue conveyance and mRNA expression of COL1A1 quality in a gel-producing is as of now obscure. This consider cloned the cDNA of COL1A1 quality (GenBank promotion number: MK641512) from six N. coibor angle. The conveyance and mRNA expression design of COL1A1 was analyzed in eight tissues[1].

The COL1A1 cDNA had a full length of 6130 bp and contained a 4344 bp open perusing outline (ORF) encoding a polypeptide of 1448 amino acids. The homology of COL1A1 amino corrosive had 98% closeness with Larimichthys crocea, showing conservatism with other individuals in same family (Sciaenidae). The concluded polypeptide contained the same flag peptides, C-propeptide and N-propeptide spaces, and triple helix spaces, which are the characteristics of sort I collagen in vertebrates. The mRNA of COL1A1 quality was communicated essentially higher within the spine of than in all other tissues (P<0.05), taken after by swim bladder, skin and scales [2].

The swim bladder had higher collagen and hydroxyproline substance than other tissues, taken after by spine>, scales> and >skin (P<0.05). Our ponder effectively cloned the COL1A1 quality from for the primary time. The COL1A1 quality contained all the highlights of collagen pro-α1(I) chain proteins, and shared tall homology with other marine teleost. COL1A1 quality in is exceedingly communicated in spine and swim bladder, reliable with collagen dissemination [3].

Our think about contribute, Next-Generation Sequencing (NGS) of improved Ig qualities is an compelling innovation for recognizing pathologic clonal cells in different Myeloma (MM) and following negligible leftover malady. The clinical impact of executing NGS in Ig quality clonality investigation was assessed by means of a review chart audit. A add up to of 312 patients analyzed with MM were enlisted within the think about [4].

Ig quality clonality was decided by part investigation utilizing BIOMED-2 multiplex PCR tests and by NGS utilizing the LymphoTrack IGH FR1 Test and LymphoTrack IGK Measure. The clonality location rates in demonstrative tests gotten utilizing part investigation and NGS were 96.7% and 95.4%, separately (measurably nonsignificant contrast; P=0.772). Among tests of patients in total reduction, the clonality discovery rates gotten utilizing part investigation and NGS were 33.3% and 60.3%, separately (factually noteworthy contrast; P=0.034. Progression-free survival was altogether longer in negative than positive patients by NGS investigation (P=0.03). Clonality location by NGS-based strategies utilizing IGH FR1 and IGK measures in schedule clinical hone is attainable, gives great clonality discovery rates in symptomatic tests, and permits checking of tests in MM patients with noteworthy prognostic value. Collagen is the biggest and most plenteous protein constituting around 250 to 350 g/kg of the whole proteins. Collagen is broadly dispersed in most organs in vertebrates. It may be a gigantic family with a wide assortment of highly complex structures, from atomic structure, supramolecular structure, to tissue conveyance and work, It is additionally connected in beauty care products and biomaterials for cell platform, wound dressing and delicate tissue enlargement. In addition, collagen plays organic capacities such as antioxidant, antimicrobial action, anti-hypertensive. It is additionally connected in beauty care products and biomaterials for cell framework, wound dressing and delicate tissue expansion. Additionally, collagen plays natural capacities such as antioxidant, antimicrobial action, anti-hypertensive and inhibitory movement and lipid-lowering impact. In this manner, collagen is an critical protein playing major parts in insusceptibility, mechanical and physiological capacities for keeping up wellbeing of skin, bones and joint. Multiple Myeloma (MM) is characterized by clonal expansion of neoplastic plasma cells in bone marrow [5].

Customarily, a few components have been known to be related with the guess of MM patients, such as cytogenetic anomalies and serum levels of β2-microglobulin, lactate dehydrogenase, and egg whites. Later myeloma treatments have accomplished tall reaction rates; in any case, most patients in the long run backslid due to the determinedly moo levels of dangerous plasma cells after treatment.


  1. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood Am J Hematol. 2018;132(23):2456-64.
  2. Indexed at, Google Scholar, Cross Ref

  3. Rustad EH, Hultcrantz M, Yellapantula VD, et al. Baseline identification of clonal V (D) J sequences for DNA-based minimal residual disease detection in multiple myeloma. PloS one. 2019;14(3):e0211600.
  4. Indexed at, Google Scholar, Cross Ref

  5. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-46.
  6. Indexed at, Google Scholar, Cross Ref

  7. Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside . Nat Rev Clin Oncol. 2015;12(5):286-95.
  8. Indexed at, Google Scholar, Cross Ref

  9. Yao Q, Bai Y, Orfao A, et al. . Upgraded standardized minimal residual disease detection by next-generation sequencing in multiple myeloma .J Mol Diagn. 2020;22(5):679-84.
  10. Indexed at, Google Scholar, Cross Ref

Get the App